Lantheus Holdings (LNTH) is drawing fresh attention after announcing that new clinical and real world oncology data will be featured at the 2026 American Society of Clinical Oncology Annual Meeting in Chicago.

The stock has pulled back slightly in the past week, but a 30 day share price return of 22.34% and year to date share price return of 47.61% suggest momentum has been building. The 5 year total shareholder return of over 3x highlights how longer term holders have been rewarded.

If developments in oncology and AI supported imaging interest you, it is worth widening your search with a screener focused on 37 healthcare AI stocks

With shares around US$99.30, Lantheus trades at a discount to the average analyst price target and to one intrinsic value estimate. This raises a core question for investors: is there still a buying opportunity here, or is the market already pricing in future growth?

Most Popular Narrative: 4.6% Undervalued

At a last close of $99.30 versus a narrative fair value of $104.08, the current price sits slightly below what the most followed model implies, and that gap is built on a detailed view of Lantheus's radiodiagnostic and royalty pipeline.

Multiple new product launches within the next 18 months, including the new F-18 PSMA PET, MK-6240, OCTEVY, and PNT2003, are set to diversify the revenue base, mitigate concentration risk, and open additional growth channels in oncology and neuroendocrine tumor imaging, supporting both top-line and future earnings expansion.

Want to see how this pipeline story turns into a valuation number? The narrative leans on measured revenue growth, firmer margins, and a future earnings multiple that sits below today’s sector average. Curious which specific assumptions have the biggest impact on that fair value gap and how sensitive the outcome is to small changes in growth?

Result: Fair Value of $104.08 (UNDERVALUED)

However, the story can shift quickly if PYLARIFY faces sharper pricing pressure than expected, or if newer radiodiagnostic launches are slower to gain traction.

Next Steps

Given the mix of enthusiasm around the pipeline and clear concerns on execution risk, it makes sense to review the full picture yourself. To see how those worries and potential upsides line up before you act, take a look at the 4 key rewards and 1 important warning sign.

Looking for more investment ideas?

If this Lantheus story caught your attention, do not stop here. Use the Simply Wall St Screener to uncover fresh opportunities that match your style.

• Target quality at a discount by reviewing companies in the 46 high quality undervalued stocks before prices move away from you.
• Focus on resilience and sleep easier at night by scanning the 62 resilient stocks with low risk scores for businesses with steadier profiles.
• Get ahead of the crowd by checking the screener containing 22 high quality undiscovered gems that combine strong fundamentals with limited market attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.